Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cadonilimab - Akeso Biopharma

Next Previous
X
Search
Drug Profile

Cadonilimab - Akeso Biopharma

Alternative Names: AK-104

Latest Information Update: 07 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer Akeso Biopharma; Chipscreen Biosciences; Hunan Cancer Hospital; Sun Yat-Sen University; The Third Affiliated Hospital of Soochow University
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cervical cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer
  • Registered Gastric cancer
  • Preregistration Oesophageal cancer
  • Phase III Liver cancer; Non-small cell lung cancer
  • Phase II Nasopharyngeal cancer; Ovarian cancer; Rectal cancer; Renal cell carcinoma; Solid tumours
  • Phase I/II Adenocarcinoma; Malignant melanoma; Pancreatic cancer; Peripheral T-cell lymphoma; Small cell lung cancer

Most Recent Events

  • 30 Sep 2024 Registered for Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV)
  • 30 Sep 2024 Akeso plans a phase III trial for Non small cell lung cancer (Unresectable/Inoperable, Late-stage disease, Second-line therapy or greater) in China (IV) in September 2024 (NCT06617416)
  • 19 Aug 2024 Akeso plans a phase II Exploratory trial for Ovarian Cancer (Combination therapy, Second-line therapy or greater) (IV) in September 2024 (NCT06560112)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top